Search for a clinical trial
Other search option(s)
41 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
AUSTRIA
STEIERMARK
GRAZ
HIT-HGG-2007: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children > 3 years and adolescents < 18 years - AT
Medizinische Universität Graz
Klinische Abteilung für pädiatrische Hämato-Onkologie
AUSTRIA
WIEN
WIEN
HERBY: A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, or Peduncular High-Grade Glioma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie
AUSTRIA
WIEN
WIEN
HIT-HGG-2007: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children > 3 years and adolescents < 18 years - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie
AUSTRIA
WIEN
WIEN
Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours With ErbB Pathway Deregulation - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
FRANCE
ILE-DE-FRANCE
VILLEJUIF
Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma - FR
CLCC Institut Gustave Roussy
Service de radiothérapie
GERMANY
Baden-Württemberg
HEIDELBERG
CATNON (EORTC 26053-22054) - Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted Anaplastic Glioma - DE
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
GERMANY
Baden-Württemberg
HEIDELBERG
Phase 1b/2a study combining LY2157299 with standard Temozolomide-based Radiochemotherapy in patients with newly diagnosed malignant Glioma - DE - Completed
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
GERMANY
Baden-Württemberg
HEIDELBERG
EORTC 26081-22086 (CODEL): Phase III intergroup study of Radiotherapy versus Temozolomide alone versus Radiotherapy with concomitant and adjuvant Temozolomide for patients with 1p/19q codeleted Anaplastic Glioma - DE
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
GERMANY
Niedersachsen
GÖTTINGEN
HIT-HGG-CilMetro: Cilengitide and Metronomic Temozolomide for relapsed or refractory high grade Gliomas or Diffuse Intrinsic Pontine Gliomas in children and adolescents - Prospective non- randomised phase II study
Universitätsmedizin Göttingen
Klinik für Kinder- und Jugendmedizin
SPAIN
Cataluña
BADALONA
The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - ES
ICO Badalona
Servicio de Oncología Radioterápica y Física Médica
SPAIN
Cataluña
ESPLUGUES DE LLOBREGAT
A Phase II Open-Label, Randomized, Multi-Centre Comparative Study of Bevacizumab-Based Therapy in Paediatric Patients With Newly Diagnosed Supratentorial High-Grade Glioma - ES
Hospital Universitari Sant Joan de Déu
Servicio de Oncología y Hematología
SPAIN
Madrid
MADRID
GEINO-13: Phase II, pilot, open label, multicenter and prospective clinical trial to evaluate the safety and activity of Palbociclib (PD0332991), a cyclin-dependent kinase 4/6 (CDK4 and CDK6) inhibitor, in patients with recurrent anaplasic oligodendroglioma or oligoastrocytome with the activity of the RB protein conserved - ES
Hospital Universitario 12 de Octubre
Unidad Multidisciplinar de Neurooncología
SPAIN
Madrid
NOT YET IDENTIFIED - ES
Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma - ES (Completed)
NOT YET IDENTIFIED - ES
UNITED KINGDOM
Greater London
LONDON
A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma - UK
Great Ormond Street Hospital for Children, NHS Foundation Trust
Haematology and oncology department
UNITED KINGDOM
Greater Manchester
NOT YET IDENTIFIED - UK
Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma - UK
NOT YET IDENTIFIED - UK
UNITED KINGDOM
Lothian
EDINBURGH
The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - UK
Edinburgh Cancer Centre
AUSTRIA
WIEN
WIEN
The TAVAREC Trial: Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas (Phase II) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
FRANCE
ILE-DE-FRANCE
PARIS
Phase III study chemotherapy vs radiotherapy in low-grade glioma
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Département de Neurologie 2 (Mazarin) : Neuro-Oncologie
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
First line chemotherapy with combination of Temozolomide (TMZ) and BCNU in newly diagnosed anaplastic oligodendrocytoma. A phase II study with translational molecular analysis
CHU de Marseille - Hôpital de la Timone
Service de neuro-oncologie
GERMANY
Baden-Württemberg
HEIDELBERG
TAVAREC (EORTC 26091) - Randomized trial assessing the significance of Bevacizumab in recurrent Grade II and Grade III Glioma (Phase II) - DE
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
GERMANY
Bayern
REGENSBURG
EORTC 22033-26033: Primary chemotherapy with Temozolomide versus Radiotherapy in patients with low grade Gliomas after stratification for genetic 1p loss: A Phase III Study
Klinik und Poliklinik für Neurologie der Universität Regensburg
Klinik und Poliklinik für Neurologie
UNITED KINGDOM
Lothian
EDINBURGH
TAVAREC: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial (Phase II) - UK
Edinburgh Cancer Centre
FRANCE
AUVERGNE-RHONE-ALPES
LYON
Randomized Phase III Study of Normal-Fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma
CLCC Léon Bérard
Comité de neuro-oncologie ; Cancérologie médicale - Pédiatrie, Tumeurs cérébrales
FRANCE
HAUTS-DE-FRANCE
LILLE
Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study
CLCC Oscar Lambret
Centre Oscar Lambret
FRANCE
ILE-DE-FRANCE
PARIS
A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Unité Fonctionnelle Epilepsie
FRANCE
ILE-DE-FRANCE
VILLEJUIF
Open Label, Pilot Phase II Study of Glivec in Children and Adolescents with Life Threatening Diseases Known to be associated with one or more Glivec-Sensitive Tyrosine Kinases - FR
CLCC Institut Gustave Roussy
Département de cancérologie de l'enfant et de l'adolescent
FRANCE
ILE-DE-FRANCE
VILLEJUIF
BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Phase II) - FR
CLCC Institut Gustave Roussy
Département de cancérologie de l'enfant et de l'adolescent #
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Primary chemotherapy with temozolomide vs radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss a phase III study
CHU de Marseille - Hôpital de la Timone
Service de neuro-oncologie
GERMANY
Bayern
AUGSBURG
SIOP-LGG-2004: Radiation therapy or combination Chemotherapy in treating Patients with clinically or radiologically progressive Low-Grade Gliomas
Klinikum Augsburg
Schwäbisches Kinderkrebszentrum
GERMANY
Niedersachsen
GÖTTINGEN
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Gliomas or Diffuse Intrinsic Pontine Glioma (Phase III) - DE
Universitätsmedizin Göttingen
Klinik für Kinder- und Jugendmedizin
GERMANY
Niedersachsen
GÖTTINGEN
HIT-HGG-2007: International cooperative phase II trials of the HIT-HGG study group for the treatment of high grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in children and adolescents 3 years and older up to 18 years
Universitätsmedizin Göttingen
Klinik für Kinder- und Jugendmedizin
NETHERLANDS
Zuid-Holland
LEIDSCHENDAM
Cognitieve Rehabilitatie van Glioom Patiënten
HMC - Haaglanden Medisch Centrum, locatie Antoniushove
Polikliniek Neurologie
SPAIN
Cataluña
ESPLUGUES DE LLOBREGAT
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors - ES
Hospital Universitari Sant Joan de Déu
Servicio de Oncología y Hematología
SPAIN
Madrid
NOT YET IDENTIFIED - ES
Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study - ES (Completed)
NOT YET IDENTIFIED - ES
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE
CNS 2007 04: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas - UK (Completed)
The Great North Children's Hospita, Royal Victoria Infirmary
Sir James Spence Institute of Child Health
DENMARK
Jylland
NOT YET IDENTIFIED - DK
FRANCE
AUVERGNE-RHONE-ALPES
NOT YET IDENTIFIED - FR
NETHERLANDS
Noord-Holland
NAARDEN
SPAIN
Cataluña
BARCELONA
A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood [...] in Paediatric Patients, Aged 2 to <18 Years, with Solid Tumours Eligible for Autologous Transplants - ES (completed)
Hospital Universitari Vall d'Hebron - Area Materno Infantil
Servicio de Oncología y Hematología Pediátricas
CANADA
Ontario
HAMILTON
FGFR Study: Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours - UK
McMaster University
Department of Medicine
UNITED KINGDOM
Greater Manchester
NOT YET IDENTIFIED - UK